vs
Side-by-side financial comparison of Global-E Online Ltd. (GLBE) and PERRIGO Co plc (PRGO). Click either name above to swap in a different company.
PERRIGO Co plc is the larger business by last-quarter revenue ($1.1B vs $625.5M, roughly 1.8× Global-E Online Ltd.). Global-E Online Ltd. runs the higher net margin — 0.9% vs -127.8%, a 128.7% gap on every dollar of revenue.
Global-E Online Ltd. operates a leading cross-border e-commerce enablement platform that helps direct-to-consumer brands and retail enterprises expand their international sales reach. It offers end-to-end services including localized checkout, payment processing, customs clearance, logistics coordination, and duty calculation, serving clients across North America, Europe, and the Asia-Pacific region.
Perrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters ...
GLBE vs PRGO — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $625.5M | $1.1B |
| Net Profit | $5.8M | $-1.4B |
| Gross Margin | 45.0% | 32.6% |
| Operating Margin | 1.3% | -116.0% |
| Net Margin | 0.9% | -127.8% |
| Revenue YoY | — | -2.5% |
| Net Profit YoY | — | -3093.9% |
| EPS (diluted) | — | $-10.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $1.1B | ||
| Q3 25 | $625.5M | $1.0B | ||
| Q2 25 | $404.8M | $1.1B | ||
| Q1 25 | $189.9M | $1.0B | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | $489.9M | $1.1B | ||
| Q2 24 | $313.9M | $1.1B | ||
| Q1 24 | $145.9M | $1.1B |
| Q4 25 | — | $-1.4B | ||
| Q3 25 | $5.8M | $7.5M | ||
| Q2 25 | $-7.4M | $-8.4M | ||
| Q1 25 | — | $-6.4M | ||
| Q4 24 | — | $-44.4M | ||
| Q3 24 | $-77.1M | $-21.0M | ||
| Q2 24 | $-54.5M | $-108.4M | ||
| Q1 24 | — | $2.0M |
| Q4 25 | — | 32.6% | ||
| Q3 25 | 45.0% | 36.1% | ||
| Q2 25 | 44.9% | 34.4% | ||
| Q1 25 | 44.3% | 37.6% | ||
| Q4 24 | — | 33.9% | ||
| Q3 24 | 45.1% | 37.2% | ||
| Q2 24 | 44.8% | 37.0% | ||
| Q1 24 | 43.4% | 33.1% |
| Q4 25 | — | -116.0% | ||
| Q3 25 | 1.3% | 7.0% | ||
| Q2 25 | -2.1% | 4.3% | ||
| Q1 25 | -10.1% | 4.5% | ||
| Q4 24 | — | 10.0% | ||
| Q3 24 | -14.9% | 7.4% | ||
| Q2 24 | -16.6% | -2.5% | ||
| Q1 24 | -20.1% | -5.1% |
| Q4 25 | — | -127.8% | ||
| Q3 25 | 0.9% | 0.7% | ||
| Q2 25 | -1.8% | -0.8% | ||
| Q1 25 | — | -0.6% | ||
| Q4 24 | — | -3.9% | ||
| Q3 24 | -15.7% | -1.9% | ||
| Q2 24 | -17.4% | -10.2% | ||
| Q1 24 | — | 0.2% |
| Q4 25 | — | $-10.23 | ||
| Q3 25 | — | $0.05 | ||
| Q2 25 | — | $-0.06 | ||
| Q1 25 | — | $-0.05 | ||
| Q4 24 | — | $-0.32 | ||
| Q3 24 | — | $-0.15 | ||
| Q2 24 | — | $-0.79 | ||
| Q1 24 | — | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $251.4M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $933.0M | $2.9B |
| Total Assets | $1.3B | $8.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | $251.4M | $432.1M | ||
| Q2 25 | $205.2M | $454.2M | ||
| Q1 25 | $207.7M | $409.9M | ||
| Q4 24 | — | $558.8M | ||
| Q3 24 | $207.3M | $1.5B | ||
| Q2 24 | $229.8M | $542.8M | ||
| Q1 24 | $181.9M | $658.5M |
| Q4 25 | — | $2.9B | ||
| Q3 25 | $933.0M | $4.4B | ||
| Q2 25 | $909.1M | $4.5B | ||
| Q1 25 | $884.3M | $4.4B | ||
| Q4 24 | — | $4.3B | ||
| Q3 24 | $869.4M | $4.6B | ||
| Q2 24 | $878.7M | $4.5B | ||
| Q1 24 | $886.9M | $4.7B |
| Q4 25 | — | $8.5B | ||
| Q3 25 | $1.3B | $10.1B | ||
| Q2 25 | $1.2B | $10.1B | ||
| Q1 25 | $1.2B | $9.8B | ||
| Q4 24 | — | $9.6B | ||
| Q3 24 | $1.2B | $11.2B | ||
| Q2 24 | $1.1B | $10.4B | ||
| Q1 24 | $1.1B | $10.6B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $175.4M |
| Free Cash FlowOCF − Capex | — | $148.6M |
| FCF MarginFCF / Revenue | — | 13.4% |
| Capex IntensityCapex / Revenue | — | 2.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $145.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $175.4M | ||
| Q3 25 | — | $51.7M | ||
| Q2 25 | — | $75.9M | ||
| Q1 25 | — | $-64.5M | ||
| Q4 24 | — | $312.6M | ||
| Q3 24 | — | $42.2M | ||
| Q2 24 | — | $9.5M | ||
| Q1 24 | — | $-1.4M |
| Q4 25 | — | $148.6M | ||
| Q3 25 | — | $29.8M | ||
| Q2 25 | — | $56.7M | ||
| Q1 25 | — | $-90.0M | ||
| Q4 24 | — | $274.9M | ||
| Q3 24 | — | $15.1M | ||
| Q2 24 | — | $-18.9M | ||
| Q1 24 | — | $-26.5M |
| Q4 25 | — | 13.4% | ||
| Q3 25 | — | 2.9% | ||
| Q2 25 | — | 5.4% | ||
| Q1 25 | — | -8.6% | ||
| Q4 24 | — | 24.2% | ||
| Q3 24 | — | 1.4% | ||
| Q2 24 | — | -1.8% | ||
| Q1 24 | — | -2.4% |
| Q4 25 | — | 2.4% | ||
| Q3 25 | — | 2.1% | ||
| Q2 25 | — | 1.8% | ||
| Q1 25 | — | 2.4% | ||
| Q4 24 | — | 3.3% | ||
| Q3 24 | — | 2.5% | ||
| Q2 24 | — | 2.7% | ||
| Q1 24 | — | 2.3% |
| Q4 25 | — | — | ||
| Q3 25 | — | 6.89× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -0.70× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GLBE
Segment breakdown not available.
PRGO
| Consumer Self Care Americas | $697.0M | 63% |
| Digestive Health | $123.9M | 11% |
| Nutrition | $108.3M | 10% |
| Healthy Lifestyle | $94.8M | 9% |
| Pain And Sleep Aids | $87.1M | 8% |
